Bristol-Myers Squibb (BMY) Tops Q1 EPS by 9c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil falls almost 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
Bristol-Myers Squibb Reports First Quarter Financial Results
April 26, 2018 6:59 AM EDTIncreases First Quarter Revenues 5% to $5.2 Billion Posts First Quarter GAAP EPS of $0.91 and Non-GAAP EPS of $0.94 Achieves Important Clinical and Regulatory Milestones in Oncology Opdivo plus Yervoy Approved in the U.S. for Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma Opdivo Four-Week Dosing Approved in the U.S. and Europe Applications for Opdivo plus Yervoy for Previously Treated Patients with MSI-H or dMMR Metastatic... More
